## FRIDAY, NOVEMBER 13, 2026

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Ballroom Level** | 11/13 | 7:30 am-7 pm | **Registration Open** | | |
| **Potomac C123** | 11/13 | 1-6:15pm | **Pediatric Obesity - Day 1 (Ticketed Event)** | | (T5, TP) |

## SATURDAY, NOVEMBER 14, 2026

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Ballroom Level** | 11/14 | 7:30 am-8:30 pm | **Registration Open** | | |
| **Potomac C123** | 11/14 | 8 am-12:45 pm | **Pediatric Obesity - Day 2 (Ticketed Event)** | | (T5, TP) |
| **Potomac D456** | 11/14 | 10:45 am-12 pm | **Basic Science Blitz Oral Session 1** | | (T1, T2, TS, TD, TN, TRx) |
| | | 10:45-11 am | **Oral-001: Translating the Gliotransmitter Octadecaneuropeptide Analog, DG-260, Into a Obesity/T2DM Therapeutic** | *Oleksandr Orativskyi* | |
| | | 11-11:15 am | **Oral-002: Weight Regulation by GLP1R Agonists via a Hypothalamic PKA-MTORC1 Mediated Pathway** | *Ritika Raghavan* | |
| | | 11:15-11:30 am | **Oral-003: Metabolic Responses to Exercise and Fasting Depend on Sympathetic-Driven Ghrelin Secretion** | *Omprakash Singh* | |
| | | 11:30-11:45 am | **Oral-005: Adipose Tissue Dynamics Vary in Different Weight Loss Intervention Types** | *Mahsheeb Khan* | |
| | | 11:45 am-noon | **Oral-006: Single PRINT™ Dose of an Incretin Agonist Reduces Body Weight in Obese Mice** | *Srivats Venkataramanan* | |
| **Riverview Ballroom A** | 11/14 | 11:45 am-1:15 pm | **Corporate Supported Symposium: Rethinking Success in the Treatment of Overweight and Obesity Through Body Composition: What Are We Made of?** | | (T3, T4, T5) |
| **Riverview Ballroom B** | 11/14 | 11:45 am-1:15 pm | **Corporate Supported Symposium: The Missing Piece in the Obesity Puzzle: Exploring the Immunobiology of Obesity and the Role of Amylin** | | (T1, T5, TRx) |
| **National Harbor 10-11** | 11/14 | 12-1 pm | **Non-CME Session: Women Inspiring and Elevating Leadership in Diabetes (WIELD): Pearls of Wisdom from Obesity Trailblazers Across Career Stages and Fields** | | |
| **National Harbor 1** | 11/14 | 12:15-1:15 pm | **TOS Policy and Advocacy Committee Meeting (invite only)** | | |
| **Potomac D456** | 11/14 | 1:15-2:30 pm | **Basic Science Blitz Oral Session 2** | | (T1, T2, TS, TD, TN, TRx) |
| | | 1:15–1:30 pm | **Oral-007: Skeletal Muscle MIRO1 Deletion Protects Against Hepatic Fibrosis via Altered Substrate Utilization** | *Analisa Taylor* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| | 11/14 | 1:30-1:45 pm | **Oral-008: Functional Coupling Between MC4R and Kir7.1 Contributes to Clozapine-Induced Obesity** | *Li Li* | |
| | | 1:45-2 pm | **Oral-009: Humans With Obesity Have Adipose Circadian Clock Disruptions in Response to Continuous Feeding** | *Kelli Lytle* | |
| | | 2-2:15 pm | **Oral-010: GLP-1 Agonists and Risk of Falls and Wheelchair Use in Older Adults** | *Deepali Ernest* | |
| | | 2:15-2:30 pm | **Oral-011: The Association of Insulin Sensitivity with Gestational Weight Gain and Gestational Diabetes** | *Jacqueline Maya* | |
| **National Harbor 2-3** | 11/14 | 1:30-2:30 pm | **Symposium: Do You Hear What I Hear? Perspectives on Food Noise** | | (T4) |
| | | 1:30-1:45 pm | **Research and Evidence on Food Noise** | *Emily Dhurandhar* | |
| | | 1:45-2 pm | **Assessment of Food Noise** | *Travis Masterson* | |
| | | 2-2:10 pm | **Patient Perspective** | *Michael Donnelly-Boylen* | |
| **Woodrow Wilson** | 11/14 | 1:30-2:30 pm | **Key Lecturer Colleen Sloan: The Evolving Plate: How Nutritional Needs Shift Throughout the Obesity Care Journey** | | (T5) |
| **Potomac C123** | 11/14 | 1:30-2:30 pm | **Symposium: Optimizing Non-Pharmacological Interventions in Pediatric Obesity** | | (T3, T5, TP) |
| | | 1:30-1:45 pm | **Effectiveness of Intensive Health Behavior and Lifestyle Interventions in Children With Obesity: Early PCORI Results** | *Bill Heerman* | |
| | | 1:45-2 pm | **Adaptive Interventions for Pediatric Obesity Non-Responders: SMART Trial Designs in Practice** | *Bethany Forseth* | |
| | | 2-2:15 pm | **Moving Beyond BMI: Alternative Outcome Targets for Behavioral Treatment of Pediatric Obesity** | *Robin Shook* | |
| **National Harbor 10-11** | 11/14 | 1:30-2:30 pm | **Treatment Access, Coverage, and Real-World Outcomes Oral Session** | | (T6) |
| | | 1:30-1:45 pm | **Oral-012: GLP-1 Therapies in the Real World: Who Starts, Who Benefits, and Who Stops** | *Alison Sexton Ward* | |
| | | 1:45-2 pm | **Oral-013: Commercial Insurance Reimbursement of Preventive Obesity Counseling: A Multi-Site Study** | *M. Rami Bailony* | |
| | | 2-2:15 pm | **Oral-014: Is There a Dose-Response Relationship Between Produce Prescription Use and Clinical Health Outcomes?** | *Cristina Lee* | |
| | | 2:15-2:30 pm | **Oral-015: Improving Outcomes in the Military Health System: Costs and Benefits of Semaglutide and Tirzepatide for Weight Loss** | *Taylor Neuman* | |
| **Potomac C123** | 11/14 | 3-4 pm | **Symposium: From Gaps to Guidance: Advancing Clinical Research in Pediatric Obesity Pharmacotherapy** | | (T5, TP, TRx) |
| | | 3-3:15 pm | **Assessing and Monitoring of Growth and Development During GLP-1 Treatment Selection, Initiation, Duration, Effects, Outcomes and Discontinuation** | *Brooke Sweeney* | |
| | | 3:15-3:30 pm | **Integrating Mental and Behavioral Health Into Obesity Care** | *Meredith Dreyer Gillette* | |
| | | 3:30-3:45 pm | **Nutrition and Physical Activity Assessment, Monitoring, and Counseling for Patients Taking GLP-1s** | *Katherine Balantekin* | |

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **National Harbor 2-3** | 11/14 | 3-4 pm | **Key Lecturer Michael Goran: Ultra-Processed Foods and the Developing Brain - A Neurodevelopmental Model of Obesity and Chronic Disease Risk** | | (T3) |
| **Woodrow Wilson** | 11/14 | 3-4 pm | **Non-CME Oral: Preclinical Obesity Pharmacotherapies and Animal Model Research Oral Session** | | (T1, TD, TP, TRx) |
| | | 3-3:15 pm | **Oral-016: Iron-Corrected T1 Reflects Ongoing Disease Activity in Paediatric MASLD** | *Luis Felipe Cardiel* | |
| | | 3:15-3:30 pm | **Oral-017: A NEK7-Selective MGD Induces Weight Loss in Mouse and Cynomolgus Monkey Models of Obesity** | *Alison Paterson* | |
| | | 3:30-3:45 pm | **Oral-018: A Long-Acting NMUR2–GIPR Dual Agonist Provides Additive Body-Weight Loss by Modulation of Complementary Satiety Pathways** | *Maximilian Lassi* | |
| | | 3:45-4 pm | **Oral-019: BPR-35000858, an ALK7-Targeting SiRNA, Demonstrates Potent Adiposity Reduction and a Favorable Safety Profile in Preclinical Mouse and Nonhuman Primate Models** | *Yu Chen* | |
| **Potomac D456** | 11/14 | 3-4 pm | **Symposium: To Gain or Not to Gain, That Is the Question - Is the Obesity Paradox a Shield or Sword as We Age?** | | (T1, T2) |
| | | 3-3:25 pm | **Human Brain Scans with Metabolic Disease Revealing Risk for Neurodegeneration** | *Kirk Erickson* | |
| | | 3:25-3:50 pm | **Cell Intrinsic Versus Extrinsic Factors in the Metabolic Defects Associated with Obesity** | *C. Ronald Kahn* | |
| **National Harbor 10-11** | 11/14 | 3-4 pm | **Symposium: What Works on the World's Plate: Global Food Policy Wins** | | (T6) |
| | | 3-3:15 pm | **Chile's Law of Food Labeling and Advertising: Evidence From the First Ten Years** | *Aline D'Angelo Campos* | |
| | | 3:15-3:30 pm | **Lessons Learned From UK Food Policy Initiatives** | *Kelly Parsons* | |
| | | 3:30-3:45 pm | **From Policy to Population Health: Mexico's Approach to Food Policy** | *Carolina Batis* | |
| **Woodrow Wilson** | 11/14 | 4:30-5:30 pm | **Symposium: Bariatric Surgery: What's New, What's True and What's Next?** | | (T5, TS, TRx) |
| | | 4:30-4:45 pm | **What's New in Bariatric Surgery - And Why It Matters Clinically** | *Enrique Elli* | |
| | | 4:45-5 pm | **What's True? Maximizing Treatment Response by ORC, Procedure, and Disease Severity (CVOT, SLEEVEPASS, High BMI, 2024 ASMBS Evidence)** | *Vance Albaugh* | |
| | | 5-5:15 pm | **What's Next? Bariatric Surgery in the ERA of OMM's, Not a Zero Sum Game** | *Sriram Machineni* | |
| **Potomac C123** | 11/14 | 4:30-5:30 pm | **Symposium: Functional Diversity of Adipose Tissue in Obesity: White, Brown, and Clinical Perspectives** | | (T1) |
| | | 4:30-4:45 pm | **Adipose Tissue Heterogeneity in the Regulation of Cardiometabolic Health** | *Paul Cohen* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| | 11/14 | 4:50-5:05 pm | **When Fat Isn't Just Fat: Brown and Beige Cells as Bioenergetic Regulators** | *Shingo Kajimura* | |
| | | 5:10-5:25 pm | **Human Adipose Tissue Dysfunction as a Driver of Metabolic Disease in Obesity** | *Susan Fried* | |
| **National Harbor 2-3** | 11/14 | 4:30-5:30 pm | **Key Lecturer Robyn Pashby: Is There a Place for Body Positivity in Obesity Care?** | | (T4) |
| **National Harbor 10-11** | 11/14 | 4:30-5:30 pm | **Long-Term Outcomes and Comparative Effectiveness of Treatments Oral Session** | | (T3, TS, TD, TRx) |
| | | 4:30-4:45 pm | **Oral-020: The Obesity Treatment Journey: Real-World Trajectories and Outcomes Across Sequential Therapies** | *Juan Garcia Cordova* | |
| | | 4:45-5 pm | **Oral-021: Comparative Effectiveness of Obesity Treatments After Semaglutide or Tirzepatide Therapy: A Target Trial Emulation** | *Hamlet Gasoyan* | |
| | | 5-5:15 pm | **Oral-022: Quality of Weight Loss With GLP-1 Receptor Agonists Versus Bariatric Surgery: A Real-World Body Composition Cohort Analysis** | *Mateo Tamayo* | |
| | | 5:15-5:30 pm | **Oral-023: Predictors of Long-Term Obesity Remission After Metabolic Surgery or Medical-Lifestyle Intervention in Patients With Type 2 Diabetes: 14-Year Findings From ARMMS-T2D** | *Philip Schauer* | |
| **Potomac D456** | 11/14 | 4:30-5:30 pm | **Non-CME Oral: Novel Therapeutic Modalities and Drug Development Oral Session** | | (T1, TD, TC, TRx) |
| | | 4:30-4:45 pm | **Oral-024: Silencing Inhbe With a GalNAc-SpiNA siRNA Drives Tissue Remodeling and a Healthy Metabolic Profile** | *Hsiu-Chiung Yang* | |
| | | 4:45-5 pm | **Oral-025: Generation of GIPR Antagonist Antibodies With Sustained Weight Loss in DIO Mice by AlfaBodY** | *Michael Chen* | |
| | | 5-5:15 pm | **Oral-026: A Peripherally Restricted GPR75 Antagonist as a First-In-Class Oral Therapy for Obesity** | *Shuguang Yuan* | |
| | | 5:15-5:30 pm | **Oral-027: Adipose-Targeted Shuttles Discovered Using AI Design and High-Throughput Vivo Screening Enable Efficient and Durable siRNA Knockdown** | *Alvaro Garcia* | |
| **Annapolis** | 11/14 | 4:30-5:30 pm | **Clinical Case Workshop: Tailoring Evidence-Based Guidelines to Meet the Needs of Patients (MOC)** | | (T5, TS, TD, TRx) |
| **Potomac AB** | 11/14 | 5:45-7 pm | **General Session: Presidential Plenary: From Discovery to Impact, Transforming Lives – Together (Non-CME)** | | (T1, T2, T3, T4, T5, T6) |
| **Exhibit Hall BCD** | 11/14 | 7-9:30 pm | **Exhibit Hall Open** | | |
| **Exhibit Hall BCD** | 11/14 | 7-9 pm | **Welcome Reception** | | |
| **Exhibit Hall BCD** | 11/14 | 7:30-8:30 pm | **Poster Session 1** | | (T1, T2) |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

## SUNDAY, NOVEMBER 15, 2026

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac Terrace** | 11/15 | 7-8 am | **Runners and Walkers Meetup** *(outdoors between atrium and pool)* | | |
| **Riverview Ballroom A** | 11/15 | 7:15-8:30 am | **Corporate Supported Symposium: Beyond the Scale: Assessing the Quality of Weight Loss and Advancing a Whole-Person Approach to Obesity Care** | | (T1, T2, T3, T4, T5, T6, TS, TRx) |
| **Ballroom Level** | 11/15 | 7:30 am-7 pm | **Registration Open** | | |
| **Exhibit Hall A** | 11/15 | 7:30-8:30 am | **Corporate Supported Symposium: Weight Management Foundayo** | | (T1, T4) |
| **Riverview Ballroom B** | 11/15 | 7:30-8:30 am | **Corporate Supported Symposium: The Obesity Treatment Journey: Evaluating Burden, Discontinuation, and Outcomes** | | (T3, T4, T5, T6, TN) |
| **National Harbor 10-11** | 11/15 | 8:30-9:30 am | **Non-CME Oral: Advancing Therapeutics: Findings From Clinical Trials Oral Session** | | (T3, T4, TD, TC) |
| | | 8:30-8:45 am | **Oral-028: Intestinal GPR17 Deficiency Increases Satiety in Rebound Hyperphagia and Improves Glucose Metabolism** | *Hongxia Ren* | |
| | | 8:45-9 am | **Oral-029: Diet Quality and Micronutrient Intake Among GLP-1-Eligible U.S. Adults: A NHANES Analysis** | *Demsina Babazadeh* | |
| | | 9-9:15 am | **Oral-030: Avexitide for Post-Bariatric Hypoglycemia: Results from the Pivotal Phase 3 LUCIDITY Trial** | *Marilyn Tan* | |
| | | 9:15-9:30 am | **Oral-031: Efficacy and Safety of CS060380, a Potent THR-β Agonist, in MASH: A Phase 2a Randomized Trial** | *Julia Yang* | |
| **National Harbor 2-3** | 11/15 | 8:30-9:30 am | **Symposium: From Kids to Older Adults: Should the 'Healthy' Use GLP-1s?** | | (T4, T5, TP, TRx) |
| | | 8:30-8:45 am | **The Role and Place of GLP-1 Use in Pediatric (Adolescents) Populations** | *Alaina Vidmar* | |
| | | 8:45-9 am | **Enhancement or Excess? GLP-1s in the Healthy Adult Populations** | *Tim Church* | |
| | | 9-9:15 am | **Do Healthy Older Adults Gain from GLP-1s?** | *John Batsis* | |
| **Woodrow Wilson** | 11/15 | 8:30-9:30 am | **Key Lecturer Eileen Seeholzer: The Affordable Toolkit - Effective Weight Management Strategies When GLP-1s Are Out of Reach (MOC)** | | (T5) |
| **Potomac D456** | 11/15 | 8:30-9:30 am | **Key Lecturer Evanna Mills: The Immune System and Regulation of Adipose Tissue** | | (T1) |
| **Potomac AB** | 11/15 | 8:30-9:30 am | **Non-CME Oral: Patient-Centered Outcomes and Experiences With GLP-1 Therapies Oral Session** | | (T3, TD, TC, TRx) |
| | | 8:30-8:45 am | **Oral-032: Effects of CagriSema on Physical and Psychosocial Function in Overweight or Obesity: REDEFINE 1** | *Domenica Rubino* | |
| | | 8:45-9 am | **Oral-033: Real-World Functional and Emotional Outcomes With GLP-1 Therapies: Early Findings From the BEACON Study** | *Cressent Pressly* | |
| | | 9-9:15 am | **Oral-034: Lived Experiences of People Living With Obesity, With or Without T2D: Implications for GLP-1RA Use** | *James Zervios* | |
| | | 9:15-9:30 am | **Oral-035: Value-Based Outcome Priorities at Entry Into a Digital GLP-1 Based Weight Management Coaching Programme** | *Zoe Griffiths* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac C123** | 11/15 | 8:30-9:30 am | **Treatment Durability and Predictors of Response Oral Session** | | (T3, TD, TP, TRx) |
| | | 8:30- 8:45 am | **Oral-036: Reasons for GLP-1 Receptor Agonist Discontinuation in Adults With Obesity: A Multi-Agent Large Language Model Analysis** | *You Chen* | |
| | | 8:45-9 am | **Oral-037: From Percent Weight Loss to Best Health: Evolution of a Treat-To-Target Framework** | *Steven Soo Huat Teoh* | |
| | | 9-9:15 am | **Oral-038: Predicting Weight Regain After GLP-1 Receptor Agonists Discontinuation: A Prognostic Model** | *Michael Romanos* | |
| | | 9:15- 9:30 am | **Oral-039: The Effectiveness of Semaglutide on Weight Change in Youths With Obesity: A Real-World Experience** | *Robert Siegel* | |
| **National Harbor 9** | 11/15 | 9–10 am | **TOS Clinical Practice Committee Meeting (invite only)** | | |
| **Exhibit Hall BCD** | 11/15 | 9:30 am-4 pm | **Exhibit Hall Open** | | |
| **Exhibit Hall BCD** | 11/15 | 9:30-10:30 am | **Coffee Break in Exhibit Hall** | | |
| **Potomac Ballroom Foyer** | 11/15 | 9:30-10:30 am | **Morning Buzz: Coffee With the Experts** | | |
| **Exhibit Hall BCD** | 11/15 | 9:45-10:15 am | **Product Theater: Evidence Snapshot-Addressing Weight and CV Risk in Patients With Obesity (Novo Nordisk)** | | |
| **National Harbor 1** | 11/15 | 10–11 am | **TOS Publications Committee Meeting (invite only)** | | |
| **Annapolis** | 11/15 | 10:30-11:30 am | **Clinical Case Workshop: How to Treat Sarcopenic Obesity and Other Comorbidities in Aging Patients Leveraging AOM and Nutrition** | | (T5) |
| **Potomac C123** | 11/15 | 10:30-11:30 am | **Exercise Training and Physiologic Adaptations Oral Session** | | (T1, TS, TD, TN) |
| | | 10:30-10:45 am | **Oral-044: Daily, Time-Restricted Exercise Restores Molecular Circadian Rhythmicity and Improves Metabolic Outcomes in a Shift Work Model** | *Montavius Coleman* | |
| | | 10:45-11 am | **Oral-045: Exercise Might Not Be a Therapeutic Strategy for Lipodystrophy in Preclinical Mouse Models** | *Andrew Lutkewitte* | |
| | | 11-11:15 am | **Oral-046: Coordinated Skeletal Muscle and Hepatic Metabolic Adaptations in Rats Following Resistance Training** | *Mitchell Sammut* | |
| | | 11:15-11:30 am | **Oral-047: Cardiorespiratory Fitness and Long-Term Weight Maintenance Following Gastric Bypass Surgery** | *Loren Smith* | |
| **National Harbor 10-11** | 11/15 | 10:30-11:30 am | **TOS/KSSO Collaborative Symposium: Unpacking Adipose Tissue - From Basic Biology to Precision Obesity Interventions** | | (T1) |
| | | 10:30-10:55 am | **Fundamentals of Fat Cell Biology Can Guide Us in Precision Medicine for the Treatment of Obesity** | *Jackie Stephens* | |
| | | 10:55-11:20 am | **Single-Cell Analysis of Human Visceral Adipose Tissue to Identify Pathophysiological Targets for Precision Obesity Interventions in Asian Populations** | *Sung Hee Choi* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **National Harbor 2-3** | 11/15 | 10:30-11:30 am | **GLP-1 Treatment Response, Utilization, and Real-World Perspectives Oral Session** | | (T4, TD, TRx) |
| | | 10:30-10:45 am | **Oral-040: GLP-1 Agonists and Substance Use Disorders in Adults With Obesity and Without Diabetes** | *Asim Mohamed* | |
| | | 10:45-11 am | **Oral-041: Weight Loss Variability and Genetic Associations Among Individuals Taking GLP-1 Receptor Agonists and Dual GLP-1/GIP-RA** | *Aastha Kakar* | |
| | | 11-11:15 am | **Oral-042: Discontinuation and Reinitiation of GLP-1 Receptor Agonists in Adults With Overweight and Obesity** | *Sainikhil Sontha* | |
| | | 11:15-11:30 am | **Oral-043: GLP-1s and Weight Stigma on TikTok: A Large-Scale Analysis of Public Discourse** | *Rui Wu* | |
| **Annapolis** | 11/15 | 10:30-11:30 am | **Clinical Case Workshop: How to Treat Sarcopenic Obesity and Other Comorbidities in Aging Patients Leveraging AOM and Nutrition** | | (T5) |
| **Potomac D456** | 11/15 | 10:30-11:30 am | **Key Lecturer Andres Acosta: Why One Size Will Never Fit All: Biological Diversity in Obesity and Treatment Response** | | (T2, T3, T5) |
| **Woodrow Wilson** | 11/15 | 10:30-11:30 am | **Key Lecturer Joy DeBellis: The Missing Link in Obesity Care - Building Resilient Habits for a Chaotic World** | | (T5) |
| **Potomac AB** | 11/15 | 10:30-11:30 am | **TOS/AANP Joint Symposium: Turn Down the Volume - Tackling Food Noise in Obesity Treatment** | | (T5, TN) |
| | | 10:30-10:55 am | **Science Behind Food Noise** | *Emily Dhurandhar* | |
| | | 10:55-11:20 am | **Clinical Implications of Food Noise** | *Angela Ritten* | |
| **Exhibit Hall BCD** | 11/15 | 11 am-3:30 pm | **Exhibit: Bark Park Open** | | |
| **Exhibit Hall BCD** | 11/15 | 11:35 am-12:05 pm | **Product Theater: Every Bite Counts - The Role of Nutrient-dense Foods in the GLP-1 Era (Almond Board of California)** | | |
| **Exhibit Hall A** | 11/15 | 11:45 am-1:15 pm | **Corporate Supported Symposium: Treating Obesity First: Exploring the Role of Amylin Analogues in the Future of Obesity Care** | | (T3, TN) |
| **Riverview Ballroom A** | 11/15 | 11:45 am-1:15 pm | **Corporate Supported Symposium: Bridging Obesity and MASLD Through Metabolic Dysfunction** | | (T1) |
| **Riverview Ballroom B** | 11/15 | 12-1 pm | **Corporate Supported Symposium: Defining Acquired Hypothalamic Obesity: An International Expert Consensus on Diagnostic Criteria in Children and Adults** | | (T6) |
| **Annapolis** | 11/15 | 12-1 pm | **TOS Neuroscience Section Meeting (TOS members only)** | | (T2) |
| **Potomac C123** | 11/15 | 12-1 pm | **TOS Bariatric Surgery and Devices Section Meeting (TOS members only)** | | (TS) |
| **Potomac D456** | 11/15 | 12-1 pm | **TOS Behavioral Science Section Meeting (TOS members only)** | | (T3, T5) |
| **Woodrow Wilson** | 11/15 | 12-1 pm | **TOS Clinical Science Section Meeting (TOS members only) - Ethical and Statistical Considerations for Obesity Research in 2026 and Beyond** | | (T3) |
| **Potomac AB** | 11/15 | 1:30-2:30 pm | **General Session: TOS Awards Plenary: Perspectives on Obesity: Science, Behavior, and the Path Forward** | | (T3, T4, T5, T6, TRx) |
| **Exhibit Hall BCD** | 11/15 | 2:30-3:30 pm | **Poster Session 2** | | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Exhibit Hall BCD** | 11/15 | 2:30-3:30 pm | **Coffee Break in Exhibit Hall** | | |
| **Annapolis** | 11/15 | 3:30-4:30 pm | **Clinical Case Workshop: Individualizing The Physical Activity Prescription Within Obesity Care: Addressing Health Goals, Health Considerations (Morbidities), and Mobility Limitations** | | |
| **National Harbor 1** | 11/15 | 3:30-4:30 pm | **TOS Science Development Committee Meeting (invite only)** | | |
| **National Harbor 10-11** | 11/15 | 3:30-4:30 pm | **Symposium: Breast Cancer - We're Treating It All Wrong** | | (T1, T3, T5) |
| | | 3:30-3:45 pm | **Lifestyle Modification to Alter Body Composition in Breast Cancer Treatment** | *Colin Champ* | |
| | | 3:50-4:05 pm | **Exercise Reduces Tumor Growth in Diet-Induced Obese Models** | *Rachel Perry* | |
| | | 4:10-4:25 pm | **Endocrine Therapy Induces Adipose Tissue Dysfunction** | *Elizabeth Wellberg* | |
| **National Harbor 2-3** | 11/15 | 3:30-4:30 pm | **Population Trends and Environmental Risk Factors Oral Session** | | (T4, TD, TN, TP) |
| | | 3:30-3:45 pm | **Oral-048: Weight-Loss Attempts Are Rising, Yet Measured Success Remains Limited: Evidence From Two Decades of National Surveillance** | *Sixtus Aguree* | |
| | | 3:45-4 pm | **Oral-049: Changing Landscape of High BMI–Related Cancers in the United States, 1990–2023** | *Digantkumar Patel* | |
| | | 4-4:15 pm | **Oral-050: Neighborhood Environments and Longitudinal Obesity Risk in the All of Us Research Program** | *Qianxia Jiang* | |
| | | 4:15-4:30 pm | **Oral-051: Para-Dichlorobenzene Exposure Linked to Elevated Visceral Fat Accumulation in Adults** | *Mary Roark* | |
| **Potomac AB** | 11/15 | 3:30-4:30 pm | **Non-CME Oral: Pharmacologic Effects on Food Cravings and Eating Behavior Oral Session** | | (T3, T6, TD, TC, TRx) |
| | | 3:30-3:45 pm | **Oral-052: The Impact of Eloralintide on Food Noise, Food Cravings and Alcohol Consumption for People With Obesity: A Qualitative Study of Phase 2 Trial Participants** | *Iris Goetz* | |
| | | 3:45-4 pm | **Oral-053: Food-As-Medicine Program Reduces Diet-Responsive Medical Costs in Multi-Morbid Obesity** | *Garima Sharma* | |
| | | 4-4:15 pm | **Oral-054: Effect of Cagrilintide 2.4 mg on Food Cravings and Eating Behavior: REDEFINE 1 Post Hoc Analysis** | *Michelle Dalton* | |
| | | 4:15-4:30 pm | **Oral-055: Changes in Eating Behavior and Food Craving with Tirzepatide Dose Reduction in SURMOUNT-MAINTAIN** | *Fatima Stanford* | |
| **Potomac C123** | | 3:30-4:30 pm | **Behavioral Pathways and Digital Innovations in Weight Management Oral Session** | | (T3, TD, TN) |
| | | 3:30-3:45 pm | **Oral-056: Optimizing a Behavioral Weight Loss Just-In-Time Adaptive Intervention: Results of the AGILE Trial** | *Brooke Nezami* | |
| | | 3:45-4 pm | **Oral-057: Early Non-Response in an MHealth Weight Loss Intervention for Adults With Socioeconomic Disadvantage** | *Amanda Montanari* | |
| | | 4-4:15 pm | **Oral-058: Psychosocial and Behavioral Pathways to Weight Loss: A Causal Discovery Analysis of PROPEL Data** | *Samantha Kennedy* | |
| | | 4:15-4:30 pm | **Oral-059: Behavioral Intervention Targeting Fat Loss in Pregnancy Reduces Gestational Weight Gain in Obesity** | *Leanne Redman* | |

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac D456** | 11/15 | 3:30-4:30 pm | **Non-CME Oral: Eloralintide Phase 2 Clinical Outcomes Oral Session** | | (T3, TD, TC) |
| | | 3:30-3:35 pm | **Oral-060: Introduction to Eloralintide and Previous Phase 1 and 2 Results** | *Gema Fruhbeck* | |
| | | 3:35-3:50 pm | **Oral-061: Eloralintide Plus Tirzepatide: Phase 2 Study Design and Baseline Characteristics** | *Stanley Hsia* | |
| | | 3:50-4:05 pm | **Oral-063: Eloralintide Plus Tirzepatide in People with Obesity and T2D: Phase 2 Efficacy Results** | *Liana Billings* | |
| | | 4:05-4:20 pm | **Oral-062: Eloralintide Plus Tirzepatide in People with Obesity and T2D: Phase 2 Efficacy Safety and Tolerability Results** | *Ania Jastreboff* | |
| | | 4:20- 4:30 pm | **Oral-064: Commentary** | *Jaime Almandoz* | |
| **Woodrow Wilson** | 11/15 | 3:30-4:30 pm | **Symposium: From Prevalence to Practice: Recognizing and Screening Eating Disorders in Adults Seeking Obesity Treatment** | | (T5, TS, TN) |
| | | 3:30-3:45 pm | **What We're Missing: Eating Disorder Risk in Adult Obesity Care** | *Janet Lydecker* | |
| | | 3:45-4 pm | **Eating Disorder Screening and Clinical Decision-Making in Bariatric Surgery Pathways** | *Abby Braden* | |
| | | 4-4:15 pm | **Patient Perspective of Lived Experience: What We Don't Say Out Loud** | *Melinda Watman* | |
| **National Harbor 12-13** | 11/15 | 4-5 pm | **TOS Finance Committee Meeting (invite only)** | | |
| **Annapolis** | 11/15 | 5-6:30 pm | **Clinical Case Workshop: The Role of Parents (Adult Caregivers) In Childhood/Adolescent Obesity Care – Changes With Developmental Needs of the Child (MOC)** | | (T5) |
| **National Harbor 10-11** | 11/15 | 5–6 pm | **Women's Health, Hormones, and Pharmacologic Response to Weight-Loss Interventions Oral Session** | | (T1, TS, TD, TRx) |
| | | 5-5:15 pm | **Oral-065: Are Postmenopausal Women "Thrifty"? Metabolic Responses to Fasting and Overfeeding** | *Edward Melanson* | |
| | | 5:15-5:30 pm | **Oral-066: A 5.5-Fold Rise in Reproductive Hormonal Disruption Links Male Obesity to Glycemic Dysregulation** | *Susan Christina Palvai* | |
| | | 5:30-5:45 pm | **Oral-067: Leptin Sensitizer ERX1000 Enhances the Metabolic Benefits of Semaglutide in Diet-Induced Obese Mice** | *Louis Aronne* | |
| | | 5:45-6 pm | **Oral-068: Exploring the Role of Obesity-Associated Extracellular Matrix in Local Breast Cancer Progression** | *Malika Sekhri* | |
| **National Harbor 2-3** | 11/15 | 5-6:30 pm | **TOS/NORC Collaborative Symposium: Novel Findings in Nutrition and Obesity Research: Highlighting NORCs' Early Career Investigators** | | (T1, T3, T5, TD, TN, TRx) |
| | | 5-5:10 pm | **NORC Early Career Training Opportunities** | *John Jakicic* | |
| | | 5:10-5:15 pm | **Mitochondrial Control of Macrophage Function in Metabolic Disease** | *Daniel Ferguson* | |
| | | 5:15-5:20 pm | **The Skin-Metabolic Axis in Chronic Inflammation** | *Sonya Wolf-Fortune* | |
| | | 5:20-5:25 pm | **Lipid Mobilization Establishes Metabolic Tolerance to Infection** | *Suraj Patel* | |
| | | 5:25-5:30 pm | **Dietary Regulation of Hematopoietic Stem Cell-Derived Adipocytes** | *Andrew Libby* | |
| | | 5:30-5:35 pm | **Unraveling the Unconventional Relationship Between Vitamin A and Incretins** | *Rossana Calderon* | |

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **National Harbor 2-3** | 11/15 | 5:35-5:40 pm | **Adiposity and Cardiometabolic Biomarkers in Adolescent PMOS** | *Rachel Whooten* | |
| | | 5:40-5:45 pm | **Use of Hypothalamic MRI in Neonates to Understand Postnatal Weight Gain** | *Leticia Sewaybricker* | |
| | | 5:45-5:50 pm | **The Human Metabolic Landscape of Cancer** | *Blake Rushing* | |
| | | 5:50-5:55 pm | **Immune Memory to Weight Loss; Implications for Weight Regain** | *Heather Caslin* | |
| | | 5:55-6pm | **Measuring Neural Gut–Brain Axis Signaling in Human Health and Obesity** | *Vance Albaugh* | |
| | | 6-6:05 pm | **The Energy Cost of Chronic Stress and Its Impact on Fat Accumulation in Adults with High Perceived Stress** | *Yenni Cedillo* | |
| | | 6:05-6:10 pm | **M3 Study: Effects of Exercise Combined with GLP-1RA on Body Composition, Fitness, and Function** | *Renee Rogers* | |
| **Potomac AB** | 11/15 | 5-6:30 pm | **Symposium: Shifting Coverage: The Evolving Insurance Landscape for Obesity Medications** | | (T6, TRx) |
| | | 5-5:20 pm | **Weighing the Costs: Cost-Effectiveness of Obesity Medications** | *Alison Sexton Ward* | |
| | | 5:20-5:40 pm | **Who's Covered by the Feds? Access to Obesity Medications in Medicare and Medicaid** | *Angela Fitch* | |
| | | 5:40-6 pm | **Private Plans, Public Impact: Commercial Coverage of Obesity Medications** | *Matthew Klebanoff* | |
| **Potomac C123** | 11/15 | 5-6 pm | **Key Lecturer Peter Smith: PATHWEIGH - Mitigating Population-Level Weight Gain in Primary Care** | | (T3, T5, T6) |
| **Potomac D456** | 11/15 | 5-6:30 pm | **Non-CME Session: *Obesity* Journal Symposium** | | (T1, T3, TS, TN, TP, TRx) |
| | | 5-5:10 pm | **Wearable-Derived Physical Activity Patterns in Preclinical and Clinical Obesity** | *Sohail Zahid* | |
| | | 5:10-5:20 pm | **A Machine Learning-Derived Gene Risk Score and Semaglutide Response in Adolescents With Obesity** | *Leslie Saba* | |
| | | 5:20-5:30 pm | **E4orf1 Preserves Fat-Free Mass Despite Significant Fat Loss during Weight Reduction** | *Vijay Hegde* | |
| | | 5:30-5:40 pm | **Adaptive Pharmacotherapy in Obesity: Intermittent, Dose-Stratified Phentermine Improves Visceral Adiposity and Body Composition** | *Oscar Torres Falcon* | |
| | | 5:40-5:50 pm | **Metabolic Differences Between Active Weight Loss and a Weight Loss Plateau** | *Ana Valencia* | |
| | | 5:50-6 pm | **GLP-1 RA Response Only After Metabolic-Bariatric Surgery** | *Tierra Sanders* | |
| | | 6-6:10 pm | **Randomized Controlled Clinical Trial Analyzing the Transcriptomics and Tumorigenesis of Adipose-Derived Stem Cells From Individuals With Obesity** | *Idiberto Jose Zotarelli-Filho* | |
| | | 6:10-6:20 pm | **Rethinking Weight-Loss-Based Treatment Decisions - Time-Dependent Early Response Thresholds** | *Katherine Spring* | |
| | | 6:20-6:30 pm | **Two-Year Weight Loss with a Breath Biofeedback mHealth Program: A Real-World Evidence Study** | *Ray Wu* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Woodrow Wilson** | 11/15 | 5-6:30 pm | **Non-CME Oral: TRIUMPH Program and SURMOUNT-ADOLESCENTS Study Oral Session** | | (T3, TD, TC, TP) |
| | | 5-5:15 pm | **Oral-069: Putting TRIUMPH into Practice: Potential Clinical Implications Across the Obesity Continuum** | *Deborah Horn* | |
| | | 5:15-5:30 pm | **Oral-070: Retatrutide in Knee Osteoarthritis: Effects on Pain and Functional Outcomes** | *Beverly Tchang* | |
| | | 5:30-5:45 pm | **Oral-071: Retatrutide in Obstructive Sleep Apnea: Apnea-Hypopnea Index and Sleep-Related Disease Burden** | *Jeremy McConnell* | |
| | | 5:45-6 pm | **Oral-072: The TRIUMPH Program: Anthropometric and Cardiometabolic Risk Factor Improvements with Retatrutide** | *Jaime Almandoz* | |
| | | 6-6:30 pm | **Oral-073-075: SURMOUNT-ADOLESCENTS**<br>**Study Methodology**<br>**Participant Disposition**<br>**Efficacy and Patiet-Reported Outcomes**<br>**Cardiometabolic Outcomes**<br>**Safety** | <br>*Gitanjali Srivastava*<br>*Marianna Rachmiel*<br>*Aaron Kelly*<br>*Daniel Hsia*<br>*Claudia Fox* | |
| | | | | | |
| **Riverview Ballroom B** | 11/15 | 6:30-8 pm | **Corporate Supported Symposium: One Patient, Many Perspectives: A Multidisciplinary Expert Roundtable on Obesity Care** | | (T1, T3, T4, T5) |
| **Riverview Ballroom A** | 11/15 | 6:30-8:30 pm | **Corporate Supported Symposium: Clinical Case Files: Following the Metabolic Clues in Obesity and MASLD** | | (T1, T5, TRx) |
| **Exhibit Hall A** | 11/15 | 6:30-9 pm | **Corporate Supported Symposium: Obesity in Focus: Today's Evidence. Tomorrow's Possibilities.** | | (T3, T5, TN, TRx) |

## MONDAY, NOVEMBER 16, 2026

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac Ballroom Foyer** (near the windows) | 11/16 | 7-8 am | **Sunrise Yoga (ticketed event)** | | |
| **Potomac Terrace** | 11/16 | 7-8 am | **Runners and Walkers Meetup**<br>(outdoors between atrium and pool) | | |
| **Riverview Ballroom A** | 11/16 | 7-8:30 am | **Corporate Supported Symposium: Beyond the Airway: Metabolic Drivers of Obstructive Sleep Apnea** | | |
| **National Harbor 4-5** | 11/16 | 7:15-8:30 am | **Breakfast Forum: Exploring Obesity Care in Primary Care Within Healthcare Systems (ticketed event)** | | |
| **Riverview Ballroom B** | 11/16 | 7:15-8:15 am | **Corporate Supported Symposium: Seen Beyond the Scale: Addressing Weight Bias and Stigma in Pediatric Obesity Care** | | |
| **Ballroom Level** | 11/16 | 7:30 am-7 pm | **Registration Open** | | |
| **Exhibit Hall A** | 11/16 | 7:30-8:30 am | **Corporate Supported Symposium: The Obesity Diagnosis You May Be Missing: Acquired Hypothalamic Obesity** | | |
| **Annapolis** | 11/16 | 8:30-9:30 am | **Clinical Case Workshop: The Hidden Challenge: Assessing Malnutrition Within Obesity Care (MOC)** | | |
| **National Harbor 10-11** | 11/16 | 8:30-9:30 am | **Key Lecturer Matthew Buman: Beyond Counting Steps: Wearables as Engines of Metabolic Change** | | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **National Harbor 2-3** | 11/16 | 8:30-9:30 am | **Symposium: Marked Before We Draw Breath: How Parental Obesity Shapes the Brain and Body** | | (T1, T2) |
| | | 8:30-8:45 am | **Maternal Obesity and Neurobehavioral Circuits in Offspring** | *Kellie Tamashiro* | |
| | | 8:45-9 am | **Parental Metabolic State Programming of Development** | *Qi Chen* | |
| | | 9-9:15 am | **Molecular Mechanisms Underlying the Effects of Exercise to Reverse the Detrimental Effects of Maternal Obesity on Offspring Health** | *Laurie Goodyear* | |
| **Potomac AB** | 11/16 | 8:30-9:30 am | **Non-CME Oral: Brain Biology, Gene Therapy, and Treatment Outcomes Oral Session** | | (T2, T4, TD, TC, TP) |
| | | 8:30-8:45 am | **Oral-076: Restoration of the Leptin-Melanocortin Pathway via Hypothalamic AAV-BDNF Rescues Syndromic Obesity** | *Josefa Sullivan* | |
| | | 8:45-9 am | **Oral-077: Transcriptomic Atlas of Human Brain Feeding Centers** | *Linh Vong* | |
| | | 9-9:15 am | **Oral-078: Increasing Burden of Obesity and Severe Obesity Among Medicare Beneficiaries, 1999–2023** | *Paul Muntner* | |
| | | 9:15-9:30 am | **Oral-079: GLP-1 Treatments Improve Behavioural and Mental Health Outcomes Through Multiple Pathways: Real-World Evidence From a UK Digital Pharmacy** | *Zoe Lees* | |
| **Potomac C123** | 11/16 | 8:30-9:30 am | **TOS/ACSM Joint Symposium: Moving Beyond Weight - Physiological and Psychological Engagement for Physical Activity in Obesity Treatment** | | (T1, T3, T5, TD, TRx) |
| | | | **Meeting Patients Where They Are At** | *Renee Rogers* | |
| | | | **The Power of Movement and Fitness for Mortality and Disease Risk** | *Tim Church* | |
| **Potomac D456** | 11/16 | 8:30-9:30 am | **TOS/ASMBS Joint Symposium: Horizons in Collaborative Obesity Treatment (MOC)** | | (T5, TS, TRx) |
| | | 8:30-8:45 am | **Anti-Obesity Medications Pre/Post Metabolic and Bariatric Surgery** | *John Morton* | |
| | | 8:45-9 am | **Published and Real World Evidence of Anti-Obesity Medications and Metabolic and Bariatric Surgery** | *Ali Aminian* | |
| | | 9-9:15 am | **The Future of Obesity Medicine and Metabolic and Bariatric Surgery** | *Jonathan Purnell* | |
| **Woodrow Wilson** | 11/16 | 8:30-9:30 am | **Symposium: LEAP Trial: Long-Term Effectiveness of the Obesity Medication Phentermine** | | (T3, T5, T6, TRx) |
| | | 8:30-8:40 am | **LEAP Trial: Rationale** | *Jamy Ard* | |
| | | 8:40-8:50 am | **LEAP Trial: Design** | *Nicholas Pajewski* | |
| | | 8:50-9 am | **LEAP Trial: Results** | *Kristina Lewis* | |
| | | 9-9:10 am | **Implications of the LEAP Trial for Clinical Practice** | *Kimberly Gudzune* | |
| **Exhibit Hall BCD** | 11/16 | 9:30 am-4 pm | **Exhibit Hall Open** | | |
| **Exhibit Hall BCD** | 11/16 | 9:30-10 am | **Coffee Break in Exhibit Hall** | | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Annapolis** | 11/16 | 10-11:30 am | **Clinical Case Workshop: Nutrition Decisions: The Live Challenge** | | |
| **National Harbor 10-11** | 11/16 | 10-11:30 am | **Non-CME Session: Early Career Lightning Talks** | | (T1, T2, T3, T4, T6) |
| | | 10-10:05 am | **Prevalence of Obesity Using the Revised Lancet Commission Criteria Among Women With a History of Breast Cancer** | *Florence Porterfield* | |
| | | 10:05-10:10 am | **Comparing Diet Quality and Dietary Behaviors Among US Black Women by Nativity in the CPS-3 Cohort** | *Jasmine Charter-Harris* | |
| | | 10:10-10:15 am | **Maximum Early-Period Weight Loss (Months 1–3) Predicts 12-Month GLP-1 Response in a Real-World Cohort** | *Hans Johnson* | |
| | | 10:15-10:20 am | **Effect of Exercise Timing and Feeding Status on Energy Metabolism During Aerobic Exercise in Humans** | *Matthew Breit* | |
| | | 10:20-10:25 am | **Obesity-Related Genetic Variants and MRI-Derived Hypothalamic Gliosis in the Framingham Heart Study** | *Dabin Yeum* | |
| | | 10:25-10:30 am | **Graded Cardiometabolic Benefits Across Weight-Loss Response With GLP-1-Based Therapies** | *Jose Villamarin* | |
| | | 10:30-10:35 am | **Exercise-Induced Energy Compensation Is Mediated by Habitual Activity Metabolic Economy** | *Tzachi Knaan* | |
| | | 10:35-10:40 am | **Obesity Treatment After Implementation of a Weight Management Program in Safety-Net Primary Care** | *Alejandro Campos* | |
| | | 10:40-10:45 am | **Patient- and System-Level Determinants of Time to GLP-1 Initiation for Obesity in Safety-Net Primary Care** | *Alejandro Campos* | |
| | | 10:45-10:50 am | **Polygenic Risk for BMI and Childhood Obesity: Effects With Maternal Gestational Diabetes in a Prospective Cohort** | *Yun Shen* | |
| **National Harbor 2-3** | 11/16 | 10-11:30 am | **TOS/NCCOR Collaborative Symposium: Assessing Capacity to Address Obesity Using Whole-of-Systems Approaches for Cancer Prevention and Control** | | (T4) |
| | | 10-10:10 am | **Assessing Capacity to Address Obesity Using Whole of Systems Approaches for Cancer Prevention and Control: Lessons Learned from One-Year of Relationship Building** | *Jill Reedy* | |
| | | 10:10-10:30 am | **Systems-level Opportunities and Solutions (SOS) to Address Obesity for Cancer Prevention and Control in Connecticut** | *Melinda Irwin* | |
| | | 10:30-10:50 am | **Building Capacity to Address Obesity in the State of Kansas in Collaboration with Community Organizations** | *Christie Befort* | |
| | | 10:50- 11:10 am | **Building a Whole-of-Systems Research Framework to Address Obesity as a Mechanism for Cancer Prevention and Control in Minnesota** | *Melissa Laska* | |
| **Potomac AB** | 11/16 | 10-11:30 am | **Non-CME Oral: Semaglutide for the Treatment of Childhood Obesity: Results of the STEP-YOUNG Trial** | | (T3, TD, TC, TP, TRx) |
| | | 10-10:15 am | **STEP-YOUNG: Background and Framing** | *Martin Wabitsch* | |
| | | 10:15-10:30 am | **STEP-YOUNG: Trial Design and Participant** | *Michelle Van Name* | |
| | | 10:30-10:45 am | **STEP-YOUNG: Efficacy Resultss** | *Ania Jastreboff* | |
| | | 10:45-11 am | **STEP-YOUNG: Safety Results** | *Antje Korner* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac AB** | 11/16 | 11-11:15 am | **STEP-YOUNG: Commentary** | *Daniel Hsia* | |
| **Potomac C123** | 11/16 | 10-11:30 am | **Symposium: Though the Brain Be Noble, the Gut Is Not Silent: Neural Plasticity of the Gut-Brain Axis** | | (T2) |
| | | 10-10:20 am | **Gut-Brain Interactions in the Regulation of Feeding Behavior** | *Laura Rupprecht* | |
| | | 10:20-10:40 am | **Plasticity and Feeding Behavior** | *Henning Fenselau* | |
| | | 10:40-11 am | **Clinical Perspectives on the Brain and Feeding Behavior** | *Valerie Darcey* | |
| **Potomac D456** | 11/16 | 10:15-11 am | **Precision Medicine, Artificial Intelligence, and Predictive Modeling Oral Session** | | (T3, TD, TRx) |
| | | 10:15-10:30 am | **Oral-081: Machine-Learning Assisted Gene Risk Score for Satiation Predicts Tirzepatide Weight-Loss Response** | *Juan Garcia Cordova* | |
| | | 10:30-10:45 am | **Oral-082: An XGBoost Machine Learning Model to Predict Visceral Adipose Tissue in the Framingham Heart Study Cohort** | *Kathleen Robinson* | |
| | | 10:45-11 am | **Oral-083: Integrative Omics and GSEA Highlight Mechanisms of Semaglutide Action in Overweight/Obese Population** | *Absalon Gutierrez* | |
| **Exhibit Hall BCD** | 11/16 | 11 am-3:30 pm | **Exhibit: Bark Park Open** | | |
| **National Harbor 12-13** | 11/16 | 11:30 am-1 pm | **TOS Program Committee Meeting (invite only)** | | |
| **Riverview Ballroom A** | 11/16 | 11:30 am-1:15 pm | **Corporate Supported Symposium: The Evolution of Obesity Management: Incorporating a Maturing Science into Clinical Practice** | | (T5, TRx) |
| **Exhibit Hall A** | 11/16 | 11:45 am-1:15 pm | **Corporate Supported Symposium: Discover Zepbound (Tirzepatide) Injection** | | (T1, T4) |
| **Riverview Ballroom B** | 11/16 | 11:45 am-12:45 pm | **Corporate Supported Symposium: Glucagon's Role in Metabolic Regulation and Why It Matters** | | (T1) |
| **Annapolis** | 11/16 | 12-1 pm | **TOS Population Science and Public Health Section Meeting (TOS members only)** | | (T4, T6) |
| **Potomac C123** | 11/16 | 12-1 pm | **TOS Metabolism and Integrative Physiology Section Meeting (TOS members only)** | | (T1) |
| **Potomac D456** | 11/16 | 12-1 pm | **TOS Pediatric Obesity Section Meeting (TOS members only)** | | (TP) |
| **Woodrow Wilson** | 11/16 | 12-1 pm | **TOS Clinical Practice Section Meeting (TOS members only) - Obesity Medicine in 2031: What Will It Look Like?** | | (T5) |
| **National Harbor 1** | 11/16 | 1-2 pm | **TOS Pediatrics Committee Meeting (invite only)** | | |
| **Annapolis** | 11/16 | 1:30-2:30 pm | **Early Career Workshop - Beyond Academia: Roadmap to What Comes Next (Non-CME)** | | (T1, T2, T3, T4, T5, T6) |
| | | 1:30-1:45 pm | **Focus on Transitioning from Academia to Industry as Early Career Researcher** | *Clare Lee* | |
| | | 1:45-2 pm | **Focus on Transitioning from Academia to Industry as Mid-Career Researcher** | *Kara Marlatt* | |
| | | 2-2:15 pm | **Focus on Transitioning from Academia to Industry as Late-Career Researcher** | *Donna Ryan* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **National Harbor 10-11** | 11/16 | 1:30-2:30 pm | **TOS/SSIB Collaborative Symposium: Much Ado About Eating - The Neurobiology of Eating Behavior** | | (T1, T2, T3, T4, T5, T6, TN, TP) |
| | | 1:30-1:45 pm | **What, Why, and How Children Eat** | *Kathleen Keller* | |
| | | 1:45-2 pm | **Palatable Food Value Learning in the Brain** | *Hyung Jin Choi* | |
| | | 2-2:15 pm | **Distinct Contributions of Pre-oral, Oral, and Post** | *Valerie Darcey* | |
| **National Harbor 2-3** | 11/16 | 1:30-2:30 pm | **Brain Biology, GLP-1 Response, and Adipose Tissue Function Oral Session** | | (T1, T2, TD, TN, TP) |
| | | 1:30-1:45 pm | **Oral-084: Pharmacologic and Physiologic Brown Adipose Tissue Activation Reveal Divergent Molecular Profiles in Humans** | *Somin Lee* | |
| | | 1:45-2 pm | **Oral-085: Improved Skeletal Muscle Metabolic Quality Following GLP-1 Receptor Agonist–Induced Weight Loss: A 7T MRI/MRS Study** | *Ryan Armbruster* | |
| | | 2-2:15 pm | **Oral-086: MRI Evidence of Gliosis Is Specific to the Hypothalamus, Not Other Appetite-Related Regions, in Children** | *Leticia Sewaybricker* | |
| | | 2:15-2:30 pm | **Oral-087: From Father to Offspring: Fish Oil Supplementation Reprograms Adipose Tissue Metabolism** | *Mariana Perez Lugo* | |
| **Potomac AB** | 11/16 | 1:30-2:30 pm | **Symposium: Beyond the Injection: Navigating the Switch to Oral Obesity Treatment Options** | | (T5, TRx) |
| | | 1:30-1:45 pm | **To Switch or Not To Switch? Access, Cost, Lifestyle Preferences, ORC Optimization** | *Gitanjali Srivastava* | |
| | | 1:45-2 pm | **Dose to Dose: What We Know, What We Assume, How to Measure Change, and Future Directions** | *Louis Aronne* | |
| | | 2-2:15 pm | **Real World Cases: The Patient Sitting in Front of You - What We Do When We Don't Know** | *Adam Gilden* | |
| **Potomac C123** | 11/16 | 1:30-2:30 pm | **Early-Life and Youth Factors Shaping Health Outcomes Oral Session** | | (T1, T4, TD, TP) |
| | | 1:30-1:45 pm | **Oral-088: Cumulative Lifestyle Risk and Overweight or Obesity at Age 3 Years in a Population-Based Study** | *Toshifumi Yoodshi* | |
| | | 1:45-2 pm | **Oral-089: The Associations Between Breastmilk Components and Eating Behaviors in Young Children** | *Ying Meng* | |
| | | 2-2:15 pm | **Oral-090: Shift Toward More Severe Obesity in Youth With Incomplete Post-Pandemic Recovery** | *Corinna Koebnick* | |
| | | 2:15-2:30 pm | **Oral-091: The Association Between First-Trimester Biomarkers and Hyperglycemia During Pregnancy** | *Ying Meng* | |
| **Potomac D456** | 11/16 | 1:30-2:30 pm | **TOS/EASO/GSA Symposium: Bridging Science and Practice for Older Adults - Integrating the 2026 EASO Staging Framework and GSA KAER Toolkit (MOC)** | | (T5) |
| | | 1:30-1:45 pm | **Beyond BMI: Identifying Phenotypes and Sarcopenic Obesity in Older Adults** | *Tiffany Cortes* | |
| | | 1:45-2 pm | **The 2026 EASO Position Statement: A New Era for Staging and Treatment Safety** | *Volkan Yumuk* | |
| | | 2-2:15 pm | **The KAER Toolkit in Action: Multimodal Management and Community Connectivity** | *Jennifer Pettis* | |

**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Woodrow Wilson** | 11/16 | 1:30-2:30 pm | **Non-CME Oral: Emerging Obesity Therapies and Clinical Outcomes Oral Session** | | (T1, T3, TD, TC, TRx) |
| | | 1:30-1:45 pm | **Oral-092: Hydroxyl Dendrimer Targeting of Macrophages and Microglia as a Novel Therapy for Obesity** | *Cindy Yang* | |
| | | 1:45-2 pm | **Oral-093: Two-Year Phase 3 Trial Results of Setmelanotide in Patients with Acquired Hypothalamic Obesity** | *Susan Phillips* | |
| | | 2-2:15 pm | **Oral-094: A First-in-Class OCN-501 Preserves Skeletal Muscle During Semaglutide-Induced Weight Loss** | *Seounghun Kang* | |
| | | 2:15-2:30 pm | **Oral-095: Clinical Factors Associated with Maintenance of Weight Reduction on Tirzepatide: SURMOUNT-MAINTAIN** | *Tina Thethi* | |
| **Exhibit Hall BCD** | 11/16 | 2:30-3:30 pm | **Poster Session 3** | | |
| **Exhibit Hall BCD** | 11/16 | 2:30-3:30 pm | **Coffee Break in Exhibit Hall** | | |
| **National Harbor 12-13** | 11/16 | 2:30-3:30 pm | **TOS CME Oversight Committee Meeting (invite only)** | | |
| **Annapolis** | 11/16 | 3:30-4:30 pm | **Symposium: Addressing Intersectional Weight Stigma: Lived Experience and Professional Perspectives** | | (T4, T5, T6) |
| | | 3:30-3:45 pm | **Navigating the Triple Stigma: Mental Health, Eating Disorders, and Obesity Care** | *Amanda Fontenot & Nanette Adams* | |
| | | 3:45-4 pm | **Beyond Assumptions: LGBTQ+ Identity, Weight Stigma, and Affirming Obesity Care** | *Daniel Lee & Guy White* | |
| | | 4-4:15 pm | **Ask, Tell, Listen: Creating Concordance in Mental Health and Obesity Care** | *Veronica Vazquez-Velazquez & Andrea Zorrilla Alonso* | |
| **National Harbor 10-11** | 11/16 | 3:30-4:30 pm | **Pediatric Obesity and Personalized Approaches to Care Oral Session** | | (T1, T3, TD, TP) |
| | | 3:30-3:45 pm | **Oral-099: Family Chaos and Change in Family Health Behaviors and Weight Loss Among Children in the TEAM up Trial** | *Keeley Pratt* | |
| | | 3:45-4 pm | **Oral-100: HealthTRAC: Integrated Emotion Regulation and Lifestyle Intervention for Adolescents With Obesity** | *Elissa Jelalian* | |
| | | 4-4:15 pm | **Oral-101: Body Composition Phenotyping Improves Type 2 Diabetes Risk Stratification** | *Saqib Abdullah Basar* | |
| | | 4:15-4:30 pm | **Oral-102: Lifestyle Treatment Versus Pharmacotherapy in Adolescents with Obesity: A Randomized Trial** | *Aaron Kelly* | |
| **Potomac AB** | 11/16 | 3:30-4:30 pm | **Blackburn Symposium (in Collaboration With ASN): Making Sense of the Dietary Guidelines - Development, Implementation, and Health Implications** | | (T6, TN) |
| | | 3:30-3:35 pm | **Blackburn Award Winner** | *John Batsis* | |
| | | 3:35-3:50 pm | **Evolving Approach to Developing Dietary Guidelines for Americans** | *Alice Lichtenstein* | |
| | | 3:50-4:05 pm | **Implications of the 2025-2030 DGAs for Health and Obesity** | *Alyssa Moran* | |
| | | 4:05-4:20 pm | **Implementation of the New DGAs in Food Programs** | *Elizabeth Solomon* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac C123** | 11/16 | 3:30-4:30 pm | **TOS/LF Collaborative Symposium: Lipedema: Rethinking Obesity Care and Research** | | (T5, TD) |
| | | 3:30-3:45 pm | **Living With Lipedema: A Patient Perspective on Diagnosis, Care and Research Impact** | *Kasi Grosvenor* | |
| | | 3:45-4 pm | **Mapping the Future of Lipedema Science** | *Ashok Srinivasan* | |
| | | 4-4:15 pm | **Why Lipedema, Why Now? A Researcher's Perspective and Pathways to Engage** | *Rachelle Crescenzi* | |
| **Potomac D456** | 11/16 | 3:30-4:30 pm | **Key Lecturer Kristy Townsend: Menopause and Hormone Therapy: New Therapeutics, New Applications** | | (T1, TN) |
| **Woodrow Wilson** | 11/16 | 3:30-4:30 pm | **Symposium: The Year in Obesity Approvals and Regulatory Updates** | | (T4, TS, TD, TN, TRx) |
| | | 3:30-4:10 pm | **The Year in Obesity Approvals and Regulatory Updates** | *Raymond Soccio* | |
| **National Harbor 2-3** | 11/16 | 3:45-4:30 pm | **Decision-Making, Nutrition, and Health Outcomes Oral Session** | | (T4, TS, TD, TN, TRx) |
| | | 3:45-4 pm | **Oral-096: "I Don't Want to Just Lose Weight; I Want to Keep It Off": A Mixed-Methods Study of Decision-Making** | *Kirstie Herb Neff* | |
| | | 4-4:15 pm | **Oral-097: Plasma Proteomic Signatures Predict Long-Term Risk for Type 2 Diabetes in Latino Adults with Obesity** | *Aditya Choubal* | |
| | | 4:15-4:30 pm | **Oral-098: Obesity Amplifies PFAS-Associated Elevated Blood Pressure in U.S. Adolescents** | *Daniel Ouyang* | |
| **Annapolis** | 11/16 | 5-6:30 pm | **Clinical Case Workshop: TOS Clinical Practice Committee Workshop: How Risk–Benefit Analyses and Obesity Treatment Decisions Change Across Generations** | | (T5, TD, TN, TP, TRx) |
| **National Harbor 10-11** | 11/16 | 5-6:30 pm | **Food Policy, Nutrition Programs, and Consumer Behavior Oral Session** | | (T6, TD, TN, TP) |
| | | 5-5:15 pm | **Oral-108: Evaluating Effects of the Introduction and Repeal of Emergency SNAP Benefits on the Healthfulness of Grocery Store Purchases** | *C. Ross Hatton* | |
| | | 5:15-5:30 pm | **Oral-109: Effects of Recommending Food Swaps on Healthfulness and Carbon Footprint of Grocery Selections** | *Anna Grummon* | |
| | | 5:30-5:45 pm | **Oral-110: Effects of Front-Of-Package Label for Non-Sugar Sweeteners on Purchasing Behavior of Brazilian Parent** | *Allison Sylvetsky* | |
| | | 5:45-6 pm | **Oral-111: Parental Perspectives on Upcoming SNAP Sweetened Beverage Restrictions in Virginia** | *Jennifer Lambert* | |
| | | 6-6:15 pm | **Oral-112: The Neighborhood Prescription: Healing Together with the Meritus Food Farmacy** | *Sarah Martin* | |
| | | 6:15-6:30 pm | **Oral-113: Changes in the Nutritional Profile of Packaged Foods After Synthetic Dye Removal** | *C. Ross Hatton* | |
| **National Harbor 2-3** | 11/16 | 5-6:30 pm | **Award Session: Ethan Sims Young Investigator Awards Competition** | | |
| **Potomac AB** | 11/16 | 5-6:30 pm | **Non-CME Oral: Advances in Weight-Loss Pharmacotherapy and Body Composition Oral Session** | | (T3, TD, TC, TRx) |
| | | 5-5:15 pm | **Oral-114: Cagrilintide a Dual Amylin and Calcitonin Receptor Agonist Protects Bone Mass During Weight Loss** | *Marco Ponzetti* | |
| | | 5:15-5:30 pm | **Oral-115: Enobosarm in Patients With Obesity on Semaglutide: Quality Weight Loss & Better Physical Function** | *K. Gary Barnette* | |

**T3** = Interventional & Clinical Studies **TC** = Corporate **TRx** = Pharmacology
**T4** = Population Health **TD** = Chronic Disease **TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac AB** | 11/16 | 5:30-5:45 pm | **Oral-116: ApoB100 Vaccination Reduces Fat Mass While Preserving Lean Mass in Obesity** | *Hyung-Ji Kim* | |
| | | 5:45-6 pm | **Oral-117: Effects of Enicepatide (CT-388) on Body Composition in Adults With Overweight or Obesity** | *Harold Bays* | |
| | | 6-6:15 pm | **Oral-118: Utreglutide (GL0034) Improves Body Weight, Body Composition and HbA1c in Adults With Type 2 Diabetes** | *Rajamannar Thennati* | |
| | | 6:15-6:30 pm | **Oral-119: Phase 2 Study of NA-931, a Quadruple Receptor Agonist, Demonstrates Significant Weight Loss With Preservation of Lean Mass** | *Lloyd Tran* | |
| **Potomac C123** | 11/16 | 5-6:30 pm | **Symposium: The Wonder Years: Treatment of Obesity in Younger Children, 6-12 Years (ABP MOC)** | | (T3, T5, T6, TN, TP, TRx) |
| | | 5-5:20 pm | **Pharmacologic Treatment of Younger Children: Newer and Off-label Therapies** | *Eric Bomberg* | |
| | | 5:20-5:40 pm | **Parent-only Interventions to Treat Obesity in Younger Children** | *Kerri Boutelle* | |
| | | 5:40-6 pm | **Treatment of Genetic and Syndromic Obesity** | *Joan Han* | |
| **Potomac D456** | 11/16 | 5-6:30 pm | **Symposium: Muscle in the Crosshairs: IMAT, GLP-1s, and the Battle for Lean Mass** | | (T1, TN, TRx) |
| | | 5-5:25 pm | **Fat Where It Doesn't Belong: Cellular Heterogeneity and Cardiometabolic Relevance of Intermuscular Adipose Tissue** | *Cheehoon Ahn* | |
| | | 5:30-5:55 pm | **Weight Loss, Pharmacotherapy, and Skeletal Muscle: What Happens Beyond the Scale** | *Brandon Roberts* | |
| | | 6-6:25 pm | **Protein and Exercise Requirements for Maintaining Muscle Mass and Function in Obesity** | *David Church* | |
| **Woodrow Wilson** | 11/16 | 5-6:30 pm | **Symposium: The Hidden Burden of Trauma in Obesity: What Health Care Professionals Need to Know (MOC)** | | (T5, TS, TN) |
| | | 5-5:10 pm | **Patient Experience: Why This Session Matters** | *Yelena Kibasova* | |
| | | 5:10-5:30 pm | **How Trauma Shapes Obesity Biology and Behavior** | *Krista Schroeder* | |
| | | 5:30-5:50 pm | **Stigma-related Trauma and Obesity Care Complexity** | *Sean Phelan* | |
| | | 5:50-6:10 pm | **Integrating Trauma Screening Into Obesity Treatment Pathways** | *Afton Koball* | |
| **Riverview Ballroom** | 11/16 | 8:30-11:30 pm | **Closing Party: Back to the 80s Bash** | | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

# TUESDAY, NOVEMBER 17, 2026

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **Potomac Terrace** | 11/17 | 7-8 am | **Runners and Walkers Meetup** (outdoors between atrium and pool) | | |
| **Ballroom Level** | 11/17 | 7:30 am-12:30 pm | **Registration Open** | | |
| **National Harbor 6-7** | 11/17 | 8 am-1 pm | **Luggage Check (free)** | | |
| **Annapolis** | 11/17 | 8:30-9:30 am | **Clinical Case Workshop: How To Measure Energy Balance and Interpret Data in Pre-Clinical Models in a Clinically Translational Way** | | (T3, T5) |
| **National Harbor 10-11** | 11/17 | 8:30-9:30 am | **Lipedema, Genetics, and Energy Balance Oral Session** | | (T1, TD, TN) |
| | | 8:30-8:45 am | **Oral-123: Vascular Dysfunction as a Driver (not Just Consequence) of Lipedema** | *Sara Al-Ghadban* | |
| | | 8:45-9 am | **Oral-124: Adenosine Receptor Axis SNPs Implicated in Obesity Phenotypes in Post Menopausal Women** | *Lydia Goss* | |
| | | 9-9:15 am | **Oral-125: Circulating Lipids Are Altered by a Microbiome Enhancer Diet and Are Associated With Energy Balance** | *Justine Mucinski* | |
| | | 9:15-9:30 am | **Oral-126: CREBRF Variant Is Associated With Higher Energy Intake but Not Lower Metabolic Rate in Samoan Adults** | *James DeLany* | |
| **Potomac C123** | 11/17 | 8:30-9:30 am | **Symposium: Unpacking the Make Our Children Healthy Again Strategy Report (ABP MOC)** | | (T6, TP) |
| | | 8:30-8:45 am | **The Rise of the MAHA Movement** | *Deena Shanker* | |
| | | 8:45-9 am | **Food Additives, Diet, and Obesity** | *Thomas Galligan* | |
| | | 9-9:15 am | **The Role of Environmental Contaminants in Obesity** | *Udayan Apte* | |
| **Potomac D456** | 11/17 | 8:30-9:30 am | **Symposium: JAMA and National Academies Present the Future of Obesity Care Delivery: Systems, Care Models, and Research** | | (T5, T6) |
| | | 8:30-8:45 am | **National Academies Roundtable on Obesity Solution Report** | *Bill Dietz* | |
| | | 8:45-9 am | **Healthcare Delivery Models From JAMA Summit** | *Louis Aronne* | |
| | | 9-9:15 am | **Action Agenda and Research Roadmap** | *Anne Cappola* | |
| **Woodrow Wilson** | 11/17 | 8:30-9:30 am | **Symposium: The Unspoken Side Effects: Navigating the Mental Shifts of Weight Loss** | | (T5) |
| | | 8:30-8:40 am | **Patient Perspective** | *Patricia Nece* | |
| | | 8:40-9 am | **When Food Stops Working: Clinical Care After MBS and Incretin Therapy** | *Gretchen Ames* | |
| | | 9-9:20 am | **The Identity Paradox: Social Dynamics and the "New" Self** | *Larissa McGarrity* | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices

| Location | Date | Time | Title | Speaker | Track |
|---|---|---|---|---|---|
| **National Harbor 2-3** | 11/17 | 8:45-9:30 am | **Predicting, Measuring, and Optimizing Treatment Response Oral Session** | | (T3, TD, TN, TRx) |
| | | 8:45-9 am | **Cardiac Structural Recovery with GLP-1 Receptor Agonists in Heart Failure: A Matched Study** | *Alfredo Verastegui* | |
| | | 9-9:15 am | **Who Benefits from Calorie Counting? Energy Intake Underreporting Predicts Weight Loss Response** | *Matthew Breit* | |
| | | 9:15-9:30 am | **Disordered Eating in Persons (BMI >27 kg/m2) Randomized to Semaglutide or Placebo for 60 Weeks** | *Kelly Allison* | |
| **National Harbor 10-11** | 11/17 | 10-11 am | **Key Lecturer Sheela Magge: Pediatric Obesity – The Effects of Body Composition, Ancestry, and Ectopic Fat on Cardiometabolic Risk** | | (T1, TP) |
| **Potomac C123** | 11/17 | 10-11 am | **Key Lecturer Roger Cone: A Receptor by Any Other Name Would Signal as Sweet - How Melanocortin Receptors Reshaped the Genetics of Obesity (Non-CME)** | | (T1, T2, T3, T5, TP, TRx) |
| **Potomac D456** | 11/17 | 10-11 am | **Key Lecturer Gail Daumit: Translating and Disseminating a Behavioral Obesity Treatment Intervention for Adults with Serious Mental Illness** | | (T3, T5, T6) |
| **National Harbor 2-3** | 11/17 | 10-11 am | **Symposium: Policy in Motion: How Changes to U.S. Food and Healthcare Policies Are Reshaping Diet and Health** | | (T6, TN, TP) |
| | | 10-10:15 am | **How Changes to SNAP Benefits and Eligibility Affect Participant Health and Wellbeing** | *Laura Samuel* | |
| | | 10:15-10:30 am | **Health Effects of Recent Changes to Medicaid** | *Seth Berkowitz* | |
| | | 10:30-10:45 am | **Impact of Universal Free School Meals on Children's Diet and Health** | *Hannah Lane* | |
| **Woodrow Wilson** | 11/17 | 10-11 am | **Symposium: Merging Modalities: A Unified Approach to Treating the Patient with BMI >35 (MOC)** | | (T5, TS, TRx) |
| | | 10-10:15 am | **Beyond Today's Medications: Emerging Pharmacotherapy and Treatment Pathways for Patients with BMI ≥35** | *Ania Jastreboff* | |
| | | 10:15-10:30 am | **Optimizing Pharmacologic Treatment for Patients With BMI ≥35: Current Evidence and Clinical Integration** | *Jamy Ard* | |
| | | 10:30-10:45 am | **Bariatric and Metabolic Surgery for BMI ≥35: Positioning Surgery Within a Modern Therapeutic Continuum** | *Crystal Johnson-Mann* | |
| **Riverview Ballroom** | 11/17 | 11 am-12:30 pm | **General Session: Brainy Brunch Trivia Throwdown** | | |

**Track Key**

**T1** = Metabolism & Integrative Physiology
**T2** = Neuroscience
**T3** = Interventional & Clinical Studies
**T4** = Population Health
**T5** = Clinical/Professional Practice
**T6** = Policy/Public Health
**TC** = Corporate
**TD** = Chronic Disease
**TN** = Nutrition
**TP** = Pediatrics
**TRx** = Pharmacology
**TS** = Bariatric Surgery & Devices